ADMS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ADMS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Adamas Pharmaceuticals's quarterly cash and cash equivalents declined from Mar. 2021 ($124.83 Mil) to Jun. 2021 ($88.80 Mil) but then stayed the same from Jun. 2021 ($88.80 Mil) to Sep. 2021 ($78.62 Mil).
Adamas Pharmaceuticals's annual cash and cash equivalents increased from Dec. 2018 ($56.61 Mil) to Dec. 2019 ($65.77 Mil) and increased from Dec. 2019 ($65.77 Mil) to Dec. 2020 ($71.66 Mil).
The historical data trend for Adamas Pharmaceuticals's Cash And Cash Equivalents can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adamas Pharmaceuticals Annual Data | |||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | ||||||||||
Cash And Cash Equivalents | Get a 7-Day Free Trial | 23.74 | 91.32 | 56.61 | 65.77 | 71.66 |
Adamas Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | |
Cash And Cash Equivalents | Get a 7-Day Free Trial | 50.80 | 71.66 | 124.83 | 88.80 | 78.62 |
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
Adamas Pharmaceuticals (NAS:ADMS) Cash And Cash Equivalents Explanation
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
Be Aware
Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.
Thank you for viewing the detailed overview of Adamas Pharmaceuticals's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.
Vijay Shreedhar | officer: Chief Commercial Officer | C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL STREET, SUITE 1000 EMERYVILLE CA 94608 |
Christopher B Prentiss | officer: Chief Financial Officer | 1900 POWELL STREET SUITE 750 EMERYVILLE CA 94608 |
Anna Richo | director | AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
David L Mahoney | director | SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014 |
Mardi Dier | director | C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301 |
William W. Ericson | director, 10 percent owner | 777 MARINERS ISLAND BOULEVARD, SUITE 550, SAN MATEO CA 94404 |
John A Macphee | director | C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL ST., SUITE 750 EMERYVILLE CA 94608 |
Ivan M Lieberburg | director | 11682 EL CAMINO REAL, SUITE 320, SAN DIEGO CA 92130 |
Michael Bigham | director | 890 WINTER STREET, WALTHAM MA 02451 |
Martha J Demski | director | 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122 |
Neil F. Mcfarlane | officer: Chief Executive Officer | C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130 |
Alfred G Merriweather | officer: Chief Financial Officer | |
Jennifer J Rhodes | officer: CBO, GC & Compliance Officer | C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608 |
Gregory T Went | director, officer: Chief Executive Officer | C/O ADAMAS PHARMACEUTICALS, INC. 2200 POWELL ST, STE 220 EMERYVILLE CA 94608 |
Rajiv Patni | officer: Chief Medical Officer | C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301 |
From GuruFocus
By Business Wire Business Wire • 10-12-2021
By PRNewswire PRNewswire • 10-27-2021
By PRNewswire PRNewswire • 11-04-2021
By ACCESSWIRE ACCESSWIRE • 10-19-2021
By Business Wire Business Wire • 07-09-2021
By Marketwired Marketwired • 10-18-2021
By Business Wire Business Wire • 08-09-2021
By Business Wire Business Wire • 10-11-2021
By PRNewswire PRNewswire • 10-20-2021
By Business Wire Business Wire • 10-01-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.